דרוג:

Nyxoah   תשתתף בכנס הבריאות השנתי ה-37 של פייפר סנדלר

מון-סן-גיבר, בלגיה – 27 בנובמבר 2025, GLOBE NEWSWIRE:

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המפתחת חלופות טיפול פורצות דרך לדום נשימה בשינה (OSA) באמצעות נוירומודולציה, הודיעה היום כי צוות ההנהלה ישתתף בשיחה ליד האח בכנס הבריאות השנתי ה-37 של פייפר סנדלר ביום חמישי, 4 בדצמבר 2025. הצ'אט ליד האח מתוכנן ל-13:30 (שעון מזרח ארה"ב) באותו יום באמצעות שידור אינטרנטי.

Nyxoah to Participate in the Piper Sandler 37^th Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – 27 November, 2025, GLOBE NEWSWIRE:

 Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contact:

Nyxoah
John Landry
Chief Financial Officer
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment

• ENGLISH_NYXH Piper Conf Advisory PR_2025

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire

לפרטים נוספים: נוי תקשורת 03-6026026 זהר 052-2641769